| Title |
Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, March 2012
|
| DOI | 10.1007/s10549-012-2013-9 |
| Pubmed ID | |
| Authors |
Daniel Prieto-Alhambra, Sonia Servitja, M. Kassim Javaid, Laia Garrigós, Nigel K. Arden, Cyrus Cooper, Joan Albanell, Ignasi Tusquets, Adolfo Diez-Perez, Xavier Nogues |
| Abstract |
Aromatase inhibitor (AI)-related bone loss is associated with increased fracture rates. Vitamin D might play a role in minimising this effect. We hypothesised that 25-hydroxy-vitamin D concentrations [25(OH)D] after 3 months supplementation might relate to bone loss after 1 year on AI therapy. We conducted a prospective cohort study from January 2006 to December 2011 of a consecutive sample of women initiating AI for early breast cancer who were ineligible for bisphosphonate therapy and stayed on treatment for 1 year (N = 232). Serum 25(OH)D was measured at baseline and 3 months, and lumbar spine (LS) bone mineral density at baseline and 1 year. Subjects were supplemented with daily calcium (1 g) and vitamin D(3) (800 IU) and additional oral 16,000 IU every 2 weeks if baseline 25(OH)D was <30 ng/ml. Linear regression models were fitted to adjust for potential confounders. After 1 year on AI therapy, 232 participants experienced a significant 1.68 % [95 % CI 1.15-2.20 %] bone loss at LS (0.017 g/cm(2) [0.012-0.024], P < 0.0001). Higher 25(OH)D at 3 months protected against LS bone loss (-0.5 % per 10 ng/ml [95 % CI -0.7 to -0.3 %], adjusted P = 0.0001), and those who reached levels ≥40 ng/ml had reduced bone loss by 1.70 % [95 % CI 0.4-3.0 %; adjusted P = 0.005] compared to those with low 25(OH)D levels (<30 ng/ml). We conclude that improved vitamin D status using supplementation is associated with attenuation of AI-associated bone loss. For this population, the current Institute of Medicine target recommendation of 20 ng/ml might be too low to ensure good bone health. |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 2% |
| Spain | 1 | 1% |
| New Zealand | 1 | 1% |
| Unknown | 86 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 14% |
| Student > Bachelor | 11 | 12% |
| Student > Ph. D. Student | 8 | 9% |
| Professor > Associate Professor | 8 | 9% |
| Other | 6 | 7% |
| Other | 19 | 21% |
| Unknown | 25 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 37% |
| Agricultural and Biological Sciences | 9 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Psychology | 3 | 3% |
| Other | 8 | 9% |
| Unknown | 29 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2012.
All research outputs
#20,169,675
of 22,681,577 outputs
Outputs from Breast Cancer Research and Treatment
#4,075
of 4,618 outputs
Outputs of similar age
#145,470
of 160,653 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#39
of 40 outputs
Altmetric has tracked 22,681,577 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,618 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 160,653 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.